PDS Biotechnology Corporation (NASDAQ:PDSB) Stock Short Interest Climbs 172.7%

PDS Biotechnology Corporation (NASDAQ:PDSB) saw a significant increase in short interest in September. As of September 15th, there was short interest totaling 6,406,521 shares, an increase of 172.7% from the August 31st total of 2,349,694 shares. Approximately 12.5% of the company’s stock are sold short. Based on an average trading volume of 97,840,279 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PDSB. Wall Street Zen cut shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Sunday. Weiss Ratings lowered PDS Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 11th. Finally, HC Wainwright reissued a “buy” rating on shares of PDS Biotechnology in a research note on Wednesday, August 26th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, PDS Biotechnology presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Institutional Trading of PDS Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp bought a new stake in PDS Biotechnology during the second quarter worth $60,000. Renaissance Technologies LLC grew its stake in PDS Biotechnology by 25.0% in the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after purchasing an additional 44,100 shares during the period. Finally, BlackRock Inc. bought a new position in PDS Biotechnology in the 2nd quarter valued at $535,000. 26.84% of the stock is owned by hedge funds and other institutional investors.

PDS Biotechnology Stock Down 3.9%

PDS Biotechnology stock opened at $0.77 on Tuesday. PDS Biotechnology has a fifty-two week low of $0.20 and a fifty-two week high of $1.55. The stock has a market cap of $42.87 million, a PE ratio of -1.20 and a beta of 1.46. The firm’s 50-day simple moving average is $0.50 and its 200 day simple moving average is $0.79. The company has a debt-to-equity ratio of 2.73, a quick ratio of 0.57 and a current ratio of 0.57.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Research analysts predict that PDS Biotechnology will post -0.47 EPS for the current fiscal year.

About PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the immune system to recognize and attack cancer cells. The company’s research is centered on its Versamune platform, which is intended to activate and enhance T-cell responses against specific disease-associated targets.

PDS Biotechnology’s lead programs include PDS0101, an investigational therapeutic candidate designed to generate immune responses against human papillomavirus type 16 (HPV16) antigens.